Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Safety-net claims emphasize disproportionate Medicaid and uncompensated care borne by 340B hospitals, whereas other analyses ...

Regulatory volatility since 2020, including IRA price negotiation, MFN pricing directives, and Medicaid best-price dynamics, ...

Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on ...

Community oncology practices face steep structural barriers to clinical trial enrollment, and pragmatic trial design that ...

FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human ...

Prior authorization remains the dominant friction point, with nearly universal reporting of delays that widen the gap between ...

SHAP ranked age, BMI, and vaginal delivery count as dominant contributors, followed by systolic blood pressure, HbA1c, PIR, ...

This study analyzes health care resource utilization and costs among patients with colorectal cancer (CRC) and ovarian cancer ...

She also predicted that drug pricing, more than access algorithms, will determine which GLP-1 becomes first-line within the ...

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care. Patients receiving injectable glucagon-like peptide-1 receptor agonist (GLP-1 ...